198 related articles for article (PubMed ID: 36709172)
41. [Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].
Shen X; Zhou LT; Li AQ; Yi HM; Ouyang BS; Xu HM; Xie JL; Gu YJ; Zhang L; Dong L
Zhonghua Bing Li Xue Za Zhi; 2022 Feb; 51(2):120-125. PubMed ID: 35152630
[No Abstract] [Full Text] [Related]
42. [Clinical characteristics and prognostic factors of 40 cases of primary systemic anaplastic large cell lymphoma].
Chen YK; Yu WJ; Liu H; Wei JY; Qian WB; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):222-227. PubMed ID: 32311892
[No Abstract] [Full Text] [Related]
43. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
Wen JJ; Liu ZB; Xu J; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
[TBL] [Abstract][Full Text] [Related]
44. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
Yang Y; Wang L; Ma Y; Han T; Huang M
Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
[TBL] [Abstract][Full Text] [Related]
45. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
46. [Analysis of clinical characteristics, treatment and survival of elderly patients with large diffuse B-cell lymphoma].
Li CY; Yang P; Dong F; Tian L; Wan W; Zhao W; Li QH; Pang M; Zhen JF; Jing HM
Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3296-3302. PubMed ID: 33202490
[No Abstract] [Full Text] [Related]
47. Evaluation of clinical and prognostic factors for primary gastric diffuse large B-cell lymphoma: Single-center experience.
Bardakci M; Esmer DD; Hafizoglu E; Karaman K; Kuzu OF; Karakas H; Gungorer B; Uncu D
J Cancer Res Ther; 2023; 19(3):778-782. PubMed ID: 37470610
[TBL] [Abstract][Full Text] [Related]
48. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
[TBL] [Abstract][Full Text] [Related]
49. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
50. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
Kobayashi T; Tsutsumi Y; Sakamoto N; Nagoshi H; Yamamoto-Sugitani M; Shimura Y; Mizutani S; Matsumoto Y; Nishida K; Horiike S; Asano N; Nakamura S; Kuroda J; Taniwaki M
Jpn J Clin Oncol; 2012 Nov; 42(11):1035-42. PubMed ID: 22984125
[TBL] [Abstract][Full Text] [Related]
51. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
[TBL] [Abstract][Full Text] [Related]
52. BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
Punnoose E; Peale FV; Szafer-Glusman E; Lei G; Bourgon R; Do AD; Kim E; Zhang L; Farinha P; Gascoyne RD; Munoz FJ; Martelli M; Mottok A; Salles GA; Sehn LH; Seymour JF; Trnĕný M; Oestergaard MZ; Mundt KE; Vitolo U
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):267-278.e10. PubMed ID: 33303421
[TBL] [Abstract][Full Text] [Related]
53. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.
Fujii K; Inagaki A; Masaki A; Sugiura M; Suzuki T; Ishida T; Kusumoto S; Iida S; Inagaki H
Ann Hematol; 2024 Jun; 103(6):2041-2050. PubMed ID: 38411628
[TBL] [Abstract][Full Text] [Related]
54. [The Effect of Bcl-6 Expression on the Prognosis of Newly Treated Double-Expressing Lymphoma Treated with R-CHOP Regimen].
Fan BJ; Chen H; Shangguan CX; Liu XY; Chang Y; Zhang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1797-1801. PubMed ID: 34893113
[TBL] [Abstract][Full Text] [Related]
55. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
[TBL] [Abstract][Full Text] [Related]
56. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
[TBL] [Abstract][Full Text] [Related]
57. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
[TBL] [Abstract][Full Text] [Related]
58. Prevalence and prognostic value of
Kirkegaard MK; Minderman M; Sjö LD; Pals ST; Eriksen PRG; Heegaard S
Br J Ophthalmol; 2023 Apr; 107(4):576-581. PubMed ID: 34706861
[TBL] [Abstract][Full Text] [Related]
59. [Expression of Bcl-2 gene and its effect on prognosis of patients with primary gastrointestinal diffuse large B-cell lymphoma].
Zhang L; Zhao H; Li X; Xia B; Zheng H; Li H; Sun B; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2014 Oct; 36(10):755-60. PubMed ID: 25567306
[TBL] [Abstract][Full Text] [Related]
60. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
Kawamoto K; Miyoshi H; Yoshida N; Nakamura N; Ohshima K; Sone H; Takizawa J
Cancer Sci; 2016 Jun; 107(6):853-61. PubMed ID: 27027803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
